Default

Why Us
Forecasts & Strategy
Get Email Alerts
Call Us : 925.263.4455

End Stage Renal Disease Dialysis Devices and Services Worldwide

Published Date: May 2008; No. of Pages: 323; Companies Profiled: 100

Price: $2495 (single-user); $4990 (Corporate)

End Stage

Description

The purpose of this research report is to analyze and quantify the market for End Stage Renal Disease (ESRD) Dialysis Devices and Services Worldwide, discuss key players, and identify trends impacting the market for these products and services. Topics discussed include product definitions, applications, types of equipment, services, market trends, disease and treatment trends, business strategies, competition, and key players. The report provides detailed market estimates and forecasts for Dialysis devices and services in U.S. dollars. Unit sales data has been provided for selected segments of the US market.

Product/Market Segment Analysis and Forecasts by Region (2005-2014)

Market estimates and forecasts for ESRD Dialysis Products and Service by country/region (US $, 2005 – 2014) for: North America (USA, Canada, Mexico); Latin America; EMEA (Africa, Middle East, Eastern Europe, UK, Spain, Portugal, Italy, France, Germany, Rest of Europe); Asia-Pacific (Japan, S. Korea, China, Taiwan, Australia, Singapore, Rest of APAC)

Detailed US market forecasts for:

ESRD Dialysis Services ($)
Hemodialysis Machines
- Institutional HD machines (units & $)
- Home HD machines (units & $)
Hemodialysis Dialyzers
- Single Use (units & $)
- Reusable (units & $)
Hemodialysis Supplies
- Blood Lines ($)
- Fistula Needles ($)
- Catheters ($)
Peritoneal Dialysis Products
- PD Cyclers (units & $)
- PD Supplies ($)

This research report can help in :

Assessing the market for ESRD Devices and Services, growth segments, and growth regions.
Understanding market drivers and restraints, and market segmentation.
Strategic planning and competitive strategy.
Identifying opportunities for partnerships and alliances.

Regions Covered

North America (USA, Canada, Mexico)
Latin America
EMEA (Africa, Middle East, Eastern Europe, UK, Spain, Portugal, Italy, France, Germany, Rest of Europe)
Asia-Pacific (Japan, S. Korea, China, Taiwan, Australia, Singapore, ROAPAC)

Discussions/Presentations in This Report Include

Executive Summary
Products, Markets, and Competitive Structure
Market Share Ranking and Competitive Position Map
Market Estimates & Forecasts by Region
Competition and Strategies
Market Drivers & Restraints
Market Trends
Company Profiles
Research Methodology
100 Market Data Tables and graphs

For table of contents in PDF format, please click here

SECTION 1 - EXECUTIVE SUMMARY

1.1. Key Takeaways

1.2. Key Market Parameters (KeyMapGrid)

1.3. Market Segmentation

Segmentation By Product Type

Segmentation by Treatment Type

Alternative Segmentation Approaches

1.4. Market Estimates, Assumptions and Data Reliability

Revenue Forecasts

Market Share Rankings and Global Competitive Position Maps

1.5. Dialysis Ecosystem

1.6. Market Drivers

1.7. Market Restraints

1.8. Growth Opportunities

1.9. Market Trends

1.10. Treatment Patterns Worldwide

1.11. ESRD Provider Trends in the US

1.12. Epidemiology

1.13. Competition

Supplier Segmentation By Business Focus

Segmentation by Company Size

Competitive Factors for Device Companies

Competitive Factors for Providers

Competitive Strategies

Products - Worldwide Market Share

1.14. World Market Forecasts

Total Market for ESRD Dialysis Products & Services - 2005-2014

ESRD Dialysis Products & Services - % Share By Region

ESRD Dialysis Products - % Share By Region

ESRD Dialysis Services - % Share By Region

1.15. Market Leaders Roundup

ARC (Asia Renal Care)

Baxter

Bridgepoint / Gambro Healthcare

B. Braun

DaVita

Euromedic

Fresenius

Gambro Renal Products

Kuratorium fur Dialyse und Nierentransplantation e.v.

SECTION 2 - PRODUCTS & TECHNOLOGY

2.1. Product Universe - Dialysis Machines/ Systems

Overview

Principles of Operation

Dialyzer Membranes for Hemodialysis

Membrane Types

Dialysis Access

2.2. Treatment Modes

Hemodialysis

Peritoneal Dialysis

Dialysis at Home

Hemofiltration

Hemodiafiltration

Continuous Renal Replacement Therapy (CRRT)

OnLine Hemodiafiltration

Prescription Dialysis

Redesigned Dialyzers

Membrane Technology

Dialysis Access

Emerging technology

2.3. Renal Dialysis Trends

Chronic Kidney Disease (CKD)

Causes of CKD

Acute versus Chronic Indications for Dialysis

Trends in Treatment

2.4. Reported Problems with Dialysis Technology

Dialysis Centers

Contaminated Water Purification Systems

Alarm failure

Dialysate

Dialyzer Reuse

Companies Discussed

Companies Profiled: 64+ Key Players; 125+ Company Briefs

Alcavis International Inc., Alphamont PTY, American Renal Associates, AngioDynamics, Inc., ARC (Asia Renal Care), Arrow International Inc. (owned byTeleflex), Artegraft Inc., Asahi Kasei Kuraray Medical Company Ltd. and Asahi Kasei Medical Co. Ltd., B Braun Medical Inc.,(Renal Therapies Division), B Braun Medical Industries Sdn Bhd (B Braun International Asia Pacific Operations), Ballya International Limited, Balton Ltd., Bard Access Systems (Div C R Bard Inc.), Bard Medical, Bard Urological , Baxter Healthcare Corporation (Renal Therapy Services Division), BD Canada, Boston Scientific (Endosurgery Group), Bridgepoint / Gambro Healthcare, C. R. Bard, Inc. , Cantel Medical Corporation, Cardinal Health, CardioMed Supplies Inc., Cardiovascular Resources, Inc., Ciposa Dialysis Sarl, Cook Inc. , Cook Medical Inc., CR Bard Inc., DaVita Inc., Debiotech SA, DEKA Research & Development Corporation, Dialysis Corporation of America, Diaverum, Dibmed Ltda., Diversified Specialty Institutes, Inc. (DSI), Euromedic, Exel International Inc., Fairbright Enterprises Inc., Fresenius Medical Care, Fresenius Medical Care North America, Gambro Group, Gambro Hospal Ltd., Gambro Renal Products, Gambro Renal Products, Hayat Tibbi Aletler San ve Tic AS, Healthcare Specialties LLC, HemaCare Corporation, Home Dialysis Plus, Hosmed Medizintechnik GmbH, Infus Medical Co.Ltd., Intra Special Catheters GmbH, Introtek International Inc., JCB Industry Ltd., Ji Hua Medical Apparatus & Instrument Co Ltd, Kawasumi Laboratories Inc., Kimal plc, Kuratorium fur Dialyse und Nierentransplantation e.v., Lifemed of California, Longreal Technology(SHENZHEN) Co., Ltd., Mar Cor Purification, Mayo Healthcare Pty Ltd., MedComp (Medical Components Inc.), Medigroup Inc., Medionics International Inc., Medisystems Corp, Melab GmbH, Mesa Laboratories, Minntech Corporation, Mitsubishi Rayon Engineering Co., Ltd., Molded Products, National Medical Industries, Nephros Inc., Nextron Medical Technologies, Nikkiso Co., LTD., Nipro Corp., Northwest Kidney Centers, OriGen Biomedical Inc., Production Engineering - Medical Equipment Division, Redi-Tech Medical Products Inc., Renal Advantage Inc., Renal Solutions Inc.,Rex Medical, Rita Medical Systems Inc., Rockwell Medical Technologies, Inc., Saint-Gobain PerformancePlastics, SCW Medicath Ltd., Sofine-Medical, Solvay Draka bv, Solmed, Sorb Technologies Spectrum Laboratories, Inc., Spire Biomedical Inc., SUPA Medical Devices, Surgimedik, Technicas Medicas Mab SA, Teijin Ltd., Terumo Medical Corp, The Dialysis Clinic Inc., Total Quality Medical, Transonic Systems Inc., Unicare Medical Services Ltd., US Renal Care Inc., Utah Medical Products Inc., VIASYS MedSystems, Vygon, WellBound, Wil-Med Global, Xcorporeal Inc.

Highlights

For report highlights in PDF format, click here

Overview

The ESRD dialysis universe includes the following products: ESRD Dialysis Services; Hemodialysis Machines (Institutional and Home HD machines); Hemodialysis Dialyzers (Single and Reusable); Hemodialysis Supplies (Blood Lines, Fistula Needles, Catheters); Peritoneal Dialysis Products (PD Cyclers, PD Supplies). A dialysis system is designed to mimic some of the functions of a kidney. It primarily performs extracorporeal dialysis to replace the main activity of the kidneys in patients with end-stage renal disease. Although it does not restore renal function or heal the kidneys, it restores a reasonable state of health by partially performing renal functions, thereby minimizing further damage to other organs and physiologic systems. Other terms for dialyzers: Artificial kidneys, Dialysis machines, Hemodialyzers, Hemodialysis machines.

Dialysis is the most common treatment for kidney failure since only about 5% of kidney failure patients are eligible for transplants, most of whom also have to depend on dialysis until a donor organ is obtained.

Key Takeaways

The world market for end-stage renal disease renal dialysis devices and services is expected to reach $64.5 billion by the end of 2008, growing at a rate of 3.7 percent per year during the 2005-2014 period.
The total number of dialysis patients worldwide is expected to reach 2 million by 2010 and 4 million by 2025..
Consolidation of service and product manufacturers across the world is set to continue, raising the entry barrier for newcomers while existing leaders tap into previously under penetrated markets and establish themselves as providers of comprehensive, cost-effective services with measurable clinical outcomes.
ESRD patient population have several co-morbidities. Market leaders have been focusing on case management strategies to improve outcomes and reduce mortality.

Key Market Drivers

A significant increase in ESRD is expected, fuelled by increases in incidence of hypertension, diabetes and obesity in conjunction with aging populations around the world. Rates of both chronic and acute renal failure are likely to increase as a result. Renal failure is a chronic worldwide epidemic, for which dialysis is the primary treatment modality.
Rapid economic growth in India and China, the two most populous nations in the world will lead to more healthcare expenditures.
Clinical evidence proposing that more frequent dialysis is more effective compared to periodic dialysis.
Market for Single-Use Dialyzers is on the upswing with Fresenius driving this segment. The company offers CarePak brand single-use therapy bundle - Optiflux high-flux dialyzes, Granuflo dry acetate concentrate, CombiSet bloodlines, and FMCNA manufactured saline.

Global Trends

US treatment trends: a) Increase in the use of Vitamin D and IV iron replacement therapy; b) Anemia correction and increase in EPO dosing; c) Continued high use of catheters, despite association with increased infectious complications and mortality.
Catheter usage is lower in Europe.
Hemodialysis is the most widely used form of dialysis therapy in most parts of the world. Peritoneal dialysis is more common in Hong Kong, Jalisco (Mexico), and Iceland.
There are significant differences in reimbursement structure and rates across Europe, with up to 100% difference in treatment rates in some cases.

Epidemiology

The total number of dialysis patients worldwide is expected to reach 2 million by 2010 and 4 million by 2025. As of 2006, the five leading countries in terms of dialysis patients were: USA (340,000), Japan (271,000), Brazil (77,000), Germany (71,000), and China (59,000). Average age of incidence of US patients has been on the rise, increasing from 53 years in 1978 to 65 years by 2002.

There has been a steady decline in standardized mortality rate for dialysis patients between 1985 and 2002 - despite increase in age and diabetes of incident patients. There is no centralized registry in Europe or APAC, like USRDS; but mortality is generally considered to be lower in Europe than the US - most likely due to the fact that diabetes is higher in incident patients in the US.

The current global trend shows an increasing incidence rate of ESRD. This trend is expected to continue due to aging populations, increase in longevity coupled with better access to healthcare and availability of reimbursement for dialysis in developing nations. Global population of elderly (65 years and over) is projected to increase at the greatest rate compared to all age groups, from about 8% in 2010 to 17% of the world’s population in 2050.

The rate of increase in new dialysis patients is highest in the most populous countries such as India and China where the annual rate is 8-10% compared to about 3-6% in developed countries. Asia is expected to have the largest dialysis population in the world by 2015.

Dialysis at Home

Dialysis can be done at home, allowing a greater quality of life. Both hemodialysis and peritoneal dialysis can be performed this way. Only 10-25% of ESRD patients are eligible for home hemodialysis since they have to have some residual kidney function and be at an earlier stage of kidney disease. Also, home hemodialysis requires a caregiver’s assistance whereas PD can be self-administered. Improved technology such as portable hemodialyis machines may promote increase home hemodialysis. Currently, however about 90% of home dialysis is PD in the US.

Reimbursement and resource availability are the most important factors, specifically these amount to:

Payment to provider
Availability of resources such as outpatient dialysis stations
Availability of trained doctors and nursing staff

In the US, clinic-centered dialysis is common due to the large number and easy access to outpatient hemodialysis centers. An additional source of income for such centers, is the reimbursement for injectable drugs such as EPO, iron and vitamin D, which are used by hemodialysis patients.

Studies show that home hemodialysis costs less and offers better patient survival than peritoneal dialysis or in-center dialysis; short, daily hemodialysis or nightly hemodialysis normalizes blood pressure and left ventricular mass and offers survival similar to live kidney donor transplants; and nightly hemodialysis improves phosphate balance so much that diet is unrestricted.

Home Hemodialysis Prevalence Varies Greatly by Country. An international study found that the prevalence of home hemodialysis is still very low and varies among some countries such as Portugal (0%) and New Zealand (25%). To assess the international use of home hemodialysis, a recent research study looked at data from renal-replacement therapy registries. The study revealed that home hemodialysis is now expanding in Finland and the Netherlands and continues to grow in New Zealand.

Competitive Activity

Leading companies in the medical beds and therapeutic surfaces space include ARC (Asia Renal Care), Baxter, Bridgepoint/Gambro, B. Braun, DaVita, Euromedic, Fresenius, Gambro Renal, and Kuratorium fur Dialyse und Nierentransplantation e.v.

Other companies in this space incldue: Alcavis International Inc., Alphamont PTY, American Renal Associates, AngioDynamics, Inc., ARC (Asia Renal Care), Arrow International Inc. (owned byTeleflex), Artegraft Inc., Asahi Kasei Kuraray Medical Company Ltd. and Asahi Kasei Medical Co. Ltd., B Braun Medical Inc.,(Renal Therapies Division), B Braun Medical Industries Sdn Bhd (B Braun International Asia Pacific Operations), Ballya International Limited, Balton Ltd., Bard Access Systems (Div C R Bard Inc.), Bard Medical, Bard Urological , Baxter Healthcare Corporation (Renal Therapy Services Division), BD Canada, Boston Scientific (Endosurgery Group), Bridgepoint / Gambro Healthcare, C. R. Bard, Inc. , Cantel Medical Corporation, Cardinal Health, CardioMed Supplies Inc., Cardiovascular Resources, Inc., Ciposa Dialysis Sarl, Cook Inc. , Cook Medical Inc., CR Bard Inc., DaVita Inc., Debiotech SA, DEKA Research & Development Corporation, Dialysis Corporation of America, Diaverum, Dibmed Ltda., Diversified Specialty Institutes, Inc. (DSI), Euromedic, Exel International Inc., Fairbright Enterprises Inc., Fresenius Medical Care, Fresenius Medical Care North America, Gambro Group, Gambro Hospal Ltd., Gambro Renal Products, Gambro Renal Products, Hayat Tibbi Aletler San ve Tic AS, Healthcare Specialties LLC, HemaCare Corporation, Home Dialysis Plus, Hosmed Medizintechnik GmbH, Infus Medical Co.Ltd., Intra Special Catheters GmbH, Introtek International Inc., JCB Industry Ltd., Ji Hua Medical Apparatus & Instrument Co Ltd, Kawasumi Laboratories Inc., Kimal plc, Kuratorium fur Dialyse und Nierentransplantation e.v., Lifemed of California, Longreal Technology(SHENZHEN) Co., Ltd., Mar Cor Purification, Mayo Healthcare Pty Ltd., MedComp (Medical Components Inc.), Medigroup Inc., Medionics International Inc., Medisystems Corp, Melab GmbH, Mesa Laboratories, Minntech Corporation, Mitsubishi Rayon Engineering Co., Ltd., Molded Products, National Medical Industries, Nephros Inc., Nextron Medical Technologies, Nikkiso Co., LTD., Nipro Corp., Northwest Kidney Centers, OriGen Biomedical Inc., Production Engineering - Medical Equipment Division, Redi-Tech Medical Products Inc., Renal Advantage Inc., Renal Solutions Inc.,Rex Medical, Rita Medical Systems Inc., Rockwell Medical Technologies, Inc., Saint-Gobain PerformancePlastics, SCW Medicath Ltd., Sofine-Medical, Solvay Draka bv, Solmed, Sorb Technologies Spectrum Laboratories, Inc., Spire Biomedical Inc., SUPA Medical Devices, Surgimedik, Technicas Medicas Mab SA, Teijin Ltd., Terumo Medical Corp, The Dialysis Clinic Inc., Total Quality Medical, Transonic Systems Inc., Unicare Medical Services Ltd., US Renal Care Inc., Utah Medical Products Inc., VIASYS MedSystems, Vygon, WellBound, Wil-Med Global, Xcorporeal Inc.